Pseudostat oral vaccine against Pseudomonas aeruginosa data

DLVRY announced results of an open label Phase I/II Australian study of Pseudostat in 9 patients with bronchiectasis, a disease of the lungs in which the structure of the bronchi is distorted so that secretions can't easily be expelled, leading to infection.

After oral vaccination at intervals over 56 days, patients had a specific T cell response against P. aeruginosa. In addition, patients showed a several-fold reduction in white cell content of the sputum, reflecting a decreased severity of infection. The number of infections requiring antibiotic therapy was reduced by two-thirds in the six months following completion of the dosing schedule. Within 28 days of discontinuing treatment, the white cells in sputum began rising. ...